Scintomics sells PentixaPharm stake to Eckert & Ziegler
Munich — Scintomics GmbH has sold its stake in PentixaPharm GmbH to Eckert & Ziegler Strahlen- und Medizintechnik AG. It was advised on the transaction by Gütt Olk Feldhaus (GOF). Part of the consideration consisted of shares in Eckert & Ziegler. The parties have agreed not to disclose the purchase price.
PentixaPharm is developing a radiopharmaceutical combination product against lymphoma and a number of related tumors that can be used for both the diagnosis and treatment of cancer. In February 2021, PentixaPharm had received confirmation from the European Medicines Agency (EMA) that its drug candidate PentixaFor can advance directly into Phase III clinical trials.
Scintomics is active in the development, licensing and commercialization of radio-pharmaceutical know-how and radiopharmaceuticals and was a founding shareholder in PentixaPharm.
Eckert & Ziegler is a listed company headquartered in Berlin, Germany, which holds interests in companies in the fields of medical and isotope technology as well as radio-pharmacy and nuclear medicine, among others.
Legal advisors to Scintomics GmbH: Gütt Olk Feldhaus, Munich
Adrian von Prittwitz (Partner, Lead), Dr. Ricarda Theis (Associate, both Corporate/M&A)
About Gütt Olk Feldhaus
Gütt Olk Feldhaus is a leading international law firm based in Munich. We provide comprehensive advice on commercial and corporate law. Our focus is on corporate law, M&A, private equity and financing. In these specialist areas we also take on the litigation.